Farran Grant

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.

Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers.